Marcus Altfeld Selected Research

HLA-B57 antigen

1/2015	Influence of Glycosylation Inhibition on the Binding of KIR3DL1 to HLA-B*57:01.
11/2013	Temporal effect of HLA-B*57 on viral control during primary HIV-1 infection.
1/2011	A novel immunodominant CD8+ T cell response restricted by a common HLA-C allele targets a conserved region of Gag HIV-1 clade CRF01_AE infected Thais.
11/2010	Early selection in Gag by protective HLA alleles contributes to reduced HIV-1 replication capacity that may be largely compensated for in chronic infection.
7/2007	Recognition of a defined region within p24 gag by CD8+ T cells during primary human immunodeficiency virus type 1 infection in individuals expressing protective HLA class I alleles.
8/2005	HLA-B63 presents HLA-B57/B58-restricted cytotoxic T-lymphocyte epitopes and is associated with low human immunodeficiency virus load.
6/2005	HIV-1 viral escape in infancy followed by emergence of a variant-specific CTL response.
12/2003	Influence of HLA-B57 on clinical presentation and viral control during acute HIV-1 infection.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Marcus Altfeld Research Topics

Disease

101	Infections 01/2022 - 02/2002
22	Disease Progression 01/2021 - 11/2004
20	Viremia 01/2019 - 04/2003
16	Virus Diseases (Viral Diseases) 10/2020 - 12/2003
16	HIV Infections (HIV Infection) 02/2017 - 04/2003
9	Persistent Infection 11/2014 - 03/2002
7	Acquired Immunodeficiency Syndrome (AIDS) 12/2016 - 08/2007
4	Inflammation (Inflammations) 01/2020 - 12/2004
4	Neoplasms (Cancer) 01/2020 - 03/2011
3	COVID-19 01/2022 - 01/2020
3	Human Influenza (Influenza) 04/2011 - 04/2004
2	Autoimmune Diseases (Autoimmune Disease) 01/2020 - 01/2017
2	Tuberculosis (Tuberculoses) 02/2017 - 01/2012
2	Sexually Transmitted Diseases (Sexually Transmitted Disease) 11/2004 - 09/2002
1	B-Cell Chronic Lymphocytic Leukemia (Chronic Lymphocytic Leukemia) 01/2021
1	Stomach Neoplasms (Stomach Cancer) 12/2020
1	Amebic Liver Abscess 10/2020
1	Inflammatory Bowel Diseases (Inflammatory Bowel Disease) 01/2020
1	Graft vs Host Disease (Graft-Versus-Host Disease) 01/2020
1	Sclerosing Cholangitis 10/2019
1	Liver Cirrhosis (Hepatic Cirrhosis) 10/2019
1	Liver Diseases (Liver Disease) 01/2019
1	Hepatocellular Carcinoma (Hepatoma) 01/2019
1	Hepatitis 01/2018
1	B-Cell Lymphoma (Lymphoma, B Cell) 01/2018
1	Non-alcoholic Fatty Liver Disease 01/2018
1	Fibrosis (Cirrhosis) 01/2017
1	Vesicular Stomatitis 04/2016
1	Endotoxemia 01/2016
1	Porcine Reproductive and Respiratory Syndrome (PRRS) 06/2015
1	Communicable Diseases (Infectious Diseases) 07/2014
1	Breakthrough Infections 06/2012
1	Coinfection 01/2012

Drug/Important Bio-Agent (IBA)

30	EpitopesIBA 01/2021 - 02/2002
22	VaccinesIBA 01/2022 - 02/2002
16	LigandsIBA 01/2021 - 09/2006
14	Antiviral Agents (Antivirals)IBA 01/2020 - 04/2007
13	AntigensIBA 09/2015 - 04/2004
12	Peptides (Polypeptides)IBA 10/2020 - 09/2002
11	CytokinesIBA 01/2016 - 05/2004
9	Proteins (Proteins, Gene)FDA Link 01/2017 - 02/2002
8	HLA-B Antigens (HLA-B)IBA 01/2019 - 12/2004
8	HLA-B57 antigenIBA 01/2015 - 12/2003
8	Interferon-gamma (Interferon, gamma)IBA 11/2014 - 04/2004
7	Natural Killer Cell ReceptorsIBA 01/2021 - 09/2006
6	AntibodiesIBA 01/2022 - 09/2004
5	Biological ProductsIBA 12/2020 - 01/2012
5	HLA-C Antigens (HLA-C)IBA 10/2019 - 08/2011
5	InterferonsIBA 10/2019 - 09/2006
5	RNA (Ribonucleic Acid)IBA 01/2019 - 04/2003
5	HLA Antigens (Human Leukocyte Antigens)IBA 01/2017 - 02/2007
4	Interferon Type IIBA 01/2022 - 04/2014
4	ChemokinesIBA 06/2015 - 12/2004
4	EnzymesIBA 11/2014 - 05/2004
4	T-Lymphocyte Epitopes (Epitopes, T Lymphocyte)IBA 09/2011 - 09/2002
4	Immunoglobulins (Immunoglobulin)IBA 08/2011 - 10/2008
3	KIR ReceptorsIBA 01/2019 - 11/2007
3	Tenofovir (Viread)FDA Link 10/2012 - 06/2012
3	HLA-Bw4 antigenIBA 06/2011 - 09/2006
3	Amino Acids FDA Link 12/2010 - 04/2004
2	Gonadal Steroid Hormones (Sex Hormones)IBA 01/2019 - 03/2016
2	Glycoproteins (Glycoprotein)IBA 04/2016 - 01/2015
2	Broadly Neutralizing AntibodiesIBA 11/2014 - 01/2011
2	Neutralizing AntibodiesIBA 11/2014 - 04/2003
2	Protein Subunits (Protein Subunit)IBA 08/2014 - 01/2012
2	Staphylococcal Protein A (Protein A)IBA 04/2014 - 10/2010
2	Interleukin-2 (IL2)IBA 01/2013 - 01/2011
2	Toll-Like Receptors (Toll-Like Receptor)IBA 03/2012 - 06/2007
2	Interleukin-10 (Interleukin 10)IBA 01/2011 - 06/2010
2	Peptide Hydrolases (Proteases)FDA Link 11/2010 - 05/2004
2	Isoleucine (L-Isoleucine)FDA Link 08/2007 - 09/2006
2	AIDS VaccinesIBA 11/2006 - 03/2006
2	HLA-A3 Antigen (HLA A3 Antigen)IBA 07/2004 - 09/2002
1	Signaling Lymphocytic Activation Molecule FamilyIBA 01/2021
1	AndrogensIBA 10/2020
1	Testosterone (Sustanon)FDA Link 10/2020
1	HLA-DP Antigens (HLA-DP)IBA 01/2020
1	Granzymes (Granzyme)IBA 10/2019
1	LipopolysaccharidesIBA 01/2019
1	CEACAM1 ProteinIBA 01/2018
1	Heme Oxygenase-1IBA 01/2017
1	Heme (Haem)IBA 01/2017
1	SteroidsIBA 01/2017
1	Cell Surface ReceptorsIBA 01/2017
1	DefensinsIBA 01/2017
1	Hormones (Hormone)IBA 01/2017
1	Aspartate Aminotransferases (Aspartate Transaminase)IBA 01/2017
1	Messenger RNA (mRNA)IBA 01/2016
1	Pathogen-Associated Molecular Pattern MoleculesIBA 06/2015
1	KIR2DL1 ReceptorsIBA 10/2014
1	Tumor Necrosis Factor-alpha (Tumor Necrosis Factor)IBA 10/2014
1	Ligases (Synthetase)IBA 04/2014
1	Biomarkers (Surrogate Marker)IBA 04/2014
1	Toll-Like Receptor AgonistsIBA 11/2013
1	Anti-Infective Agents (Microbicides)IBA 06/2012
1	Hemoglobins (Hemoglobin)IBA 01/2012

Therapy/Procedure

11	Therapeutics 09/2021 - 04/2003
6	Highly Active Antiretroviral Therapy (HAART) 07/2013 - 11/2004
3	Art Therapy 02/2017 - 09/2011
2	Liver Transplantation 01/2019 - 01/2017